Oral Presentations: Findings from Dermatological Studies
September 2017
in “
Pediatric Dermatology
”
TLDR The document concludes that an experimental drug may help wound healing in Epidermolysis Bullosa, links Hydroa vacciniforme to EBV, discusses diagnosing hair loss disorders, finds many children with eczema have allergies, reviews the safety of a skin medication in children, notes side effects of a Duchenne's treatment, and identifies a marker for pediatric mastocytosis.
The document summarizes findings from various studies on dermatological conditions, including a large clinical trial named ESSENCE for an experimental drug treating Epidermolysis Bullosa, which focused on wound closure. It also discusses two cases of Hydroa vacciniforme linked to chronic EBV infections, a review on diagnosing trichotillomania and other alopecias through histopathology, and a Danish study of 100 children with atopic dermatitis that found a 30% rate of positive patch test reactions. Additionally, it covers the safety of Acitretin in pediatric dermatology, the cutaneous side effects of Drisapersen in Duchenne's Muscular Dystrophy, and the use of sirolimus in a patient with Proteus syndrome. Other studies include the use of sirolimus in Proteus Syndrome, a study of 55 patients with CM-AVM and PWS, the efficacy of atenolol in treating infantile hemangiomas in 48 infants, a retrospective study of 370 pediatric patients with a 70% diagnosis agreement rate between emergency and dermatology departments, and a study on pediatric-onset mastocytosis involving 25 biopsy specimens from 24 patients, which identified CD30 as a sensitive marker for the condition.